Profit before payment of interest, taxes and amortization: eternatx.com (ERNA)

Eterna Therapeutics (ERNA) implements gene editing and mRNA methods to combat hematological tumors. Monitoring of EBITDA_Co demonstrates financial stability, with the indicator currently at 0.00. Development relies on Tox-T patents and licensing agreements. The project's success is based on the efficiency of cellular reprogramming combined with strict control of laboratory costs and sufficient liquidity reserves.

Eterna Therapeutics Inc. (ERNA) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/12/2026

Eterna Therapeutics Inc. (ERNA) - metric breakdowns and financial figures

- stock price and consensus target price:

Price Chart Eterna Therapeutics, Inc.|ERNA - Price Target Chart

- company stock exchange capitalization indicators:

Market Value Eterna Therapeutics|ERNA - Total Company Value

- business book valuation details:

Net Asset Value per Share Eterna Therapeutics|ERNA - Company Book Value|Market-to-Book Ratio eternatx.com|ERNA - Company Total Assets

- debt level and financial liquidity data:

- earnings and market multiples details:

ERNA - Company Net Income|Net Profit Forecast Eterna Therapeutics|ERNA - P/E Multiple|Forward P/E Multiple Eterna Therapeutics, Inc.|ERNA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Eterna Therapeutics|ERNA - Operating profit before deduction of amortization|Earnings per share for the last four quarters Eterna Therapeutics|ERNA - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months eternatx.com|ERNA - Earnings growth in current year|Expected net earnings per share growth next year Eterna Therapeutics

Fundamental company valuation:Eterna Therapeutics ERNA

Absolute operating profit measures the cash flow from core operations before interest and taxes, determining the internal efficiency of the business and its capacity for self-financing. For Eterna Therapeutics (ERNA), this operating profit summary reflects the capital's resilience to logistical disruptions and sanction restrictions within the clinical research sector, where any decline in this indicator signals a critical risk of funding shortfalls.

Who Eterna Therapeutics competes with

TG Pharma - Profit before payment of interest, taxes and amortization|ACLX - Profit before payment of interest, taxes and amortization|IRON: Profit before payment of interest, taxes and amortization|Syndax Pharmaceuticals, Inc. (SNDX) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Kura Oncology Inc (KURA)|Profit before payment of interest, taxes and amortization ADC Therapeutics Corp|Profit before interest, taxes and amortization Foghorn FHTX|Operating profit EBITDA VOR|nkartatx.com - Operating profit before amortization|Operating profit EBITDA COEP (Coeptis Therapeutics, Inc.)|Actinium Pharma (ATNM) - Profit before interest, taxes and amortization|ESLA: Operating profit before deduction of amortization|CASI Pharmaceuticals - Company profit before taxes, interest and amortization|MRKR: Operating profit EBITDA|Profit before interest, taxes and amortization in8bio.com (INAB)|Profit before payment of interest, taxes and amortization GT Biopharma|APTO: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Bio-Path (BPTH)|MEI Pharma Corporation - Operating profit before amortization|Operating profit EBITDA VINC (Vincerx Pharma)